Today, antivascular endothelial growth factor agents (anti-VEGF) are also commonly used in the treatment of ROP.[3] Both treatments have been shown to be safe and effective in the treatment of severe ROP.[4]. Here, VEGFA is linked to retinopathy of prematurity.